178 Long-term improvements in physical function of disease-modifying anti-rheumatic drug/biologic-experienced and disease-modifying anti-rheumatic drug-naïve psoriatic arthritis subjects treated with apremilast

MLA

L. Teng, et al. “178 Long-Term Improvements in Physical Function of Disease-Modifying Anti-Rheumatic Drug/Biologic-Experienced and Disease-Modifying Anti-Rheumatic Drug-Naïve Psoriatic Arthritis Subjects Treated with Apremilast.” Rheumatology, vol. 57, Apr. 2018. EBSCOhost, https://doi.org/10.1093/rheumatology/key075.402.

APA

L. Teng, Filip Van den Bosch, Alvin F. Wells, Eric Lespessailles, Christopher J Edwards, Philip J. Mease, Dianne Nguyen, Stephen Hall, & Jürgen Wollenhaupt. (2018). 178 Long-term improvements in physical function of disease-modifying anti-rheumatic drug/biologic-experienced and disease-modifying anti-rheumatic drug-naïve psoriatic arthritis subjects treated with apremilast. Rheumatology, 57. https://doi.org/10.1093/rheumatology/key075.402

Chicago

L. Teng, Filip Van den Bosch, Alvin F. Wells, Eric Lespessailles, Christopher J Edwards, Philip J. Mease, Dianne Nguyen, Stephen Hall, and Jürgen Wollenhaupt. 2018. “178 Long-Term Improvements in Physical Function of Disease-Modifying Anti-Rheumatic Drug/Biologic-Experienced and Disease-Modifying Anti-Rheumatic Drug-Naïve Psoriatic Arthritis Subjects Treated with Apremilast.” Rheumatology 57 (April). doi:10.1093/rheumatology/key075.402.